Abstract: There are few data on gynecomastia in HIV-infected children. Within the UK/Ireland's national cohort, 56 of 1873 (3%) HIV-infected children had gynecomastia, of which 10 (0.5%) were severe. All 10 had received antiretroviral therapy for a median of 27.5 (21, 42) months; 4 of 10 had received efavirenz, 7 of 10 and 6 of 10 had received stavudine and/or didanosine respectively. Five were nonreversible, despite changing antiretroviral therapy, and required breast reduction surgery.
G ynecomastia has been described in HIV-infected adults taking antiretroviral therapy (ART) and has been linked to didanosine (ddI), efavirenz (EFV) and protease inhibitors, [1] [2] [3] [4] but very few cases have been described in HIV-infected children. [5] [6] [7] [8] We explored the frequency, etiology and management of severe gynecomastia in children with perinatal HIV in the United Kingdom and Ireland's National Collaborative HIV Paediatric Study (CHIPS) cohort.
MATERIALS AND METHODS
Details of the CHIPS cohort have been published previously. 9 Cases of gynecomastia were identified from the CHIPS dataset up to April 2014, and additional case note review was undertaken to gather additional information. Severity of gynecomastia was defined as mild (minor breast enlargement, no skin redundancy) moderate (moderate breast enlargement, minor skin redundancy) or severe [in males, marked breast enlargement, major skin redundancy (resembles female breast), in females excessive breast hypertrophy interfering with everyday activities]. Descriptive statistics were calculated using Stata 13 (StataCorp, College Station, TX).
RESULTS
Of 1873 children ever in CHIPS, 52% (976) were female, 77% (1452) were black African, and the median age at last follow-up was 15 (interquartile range, 11, 17) years. A total of 56 (3%) had 58 episodes of gynecomastia, reported as mild (25), moderate (23) or severe (10) . Of the 10 severe cases, 9 were male (Table 1) . At onset the median age of severe cases was 13.5 (12, 14) years. All were receiving ART, and had been on their current regimen for a median of 27.5 (21, 42) months and on any ART regimen for 60.5 (31, 88) months. At the time of report, 5 were receiving NNRTI-based regimens (EFV 4, nevirapine 1) and 5 protease inhibitors-based regimens [ritonavirboosted lopinavir 3, nelfinavir (NVF) 2]. Current recommended NRTI included lamivudine (3TC; 6), abacavir (ABC; 4), stavudine (d4T; 4), ddI (6) and tenofovir (2). All 10 had previous or current exposure to d4T, ddI and/or EFV [7 d4T for a median of 42 (21, 74) months, 7 ddI for 21 (15, 22) months, 4 EFV for 29 (19, 39) months]. Nine of 10 young people had a body mass index (BMI) <25 (healthy/underweight) and 6 had lipodystrophy at other sites (5 of 6 had exposure to d4T; ¼ to EFV). Six patients switched ART regimens (3 patients subsequently stopped ART) with complete resolution reported within 2 years. Five patients required breast reduction surgery and 1 patient was considering surgery at the time of last follow-up. One patient transferred to adult services and their outcome is unknown.
DISCUSSION
Mild to moderate gynecomastia was relatively common in our cohort. Severe cases occurred in 1 in 200 children and were more likely in males, which may reflect difficulties in distinguishing normal pubertal development and/or obesity from pathological breast hypertrophy in girls. Only 2 severe cases occurred before 12 years of age (both on stavudine and reversed with change of ART). Thus, our findings support other reports that prepubertal gynecomastia is rare. For example, no cases were seen in the CHAPAS 3 trial in which 478 children <13 years of age, 33% on d4T were followed for a median 2.3 years. 10 Three children (ages 12, 12 and 15 years) in the ARROW trial of 1206 children (median age 6 2-9 years, 37% on EFV; none on d4T-based ART) changed regimen due to lipodystrophy/gynecomastia during 5 years of follow-up. 11 Within our cohort initial management of gynecomastia varied from immediate change of ART regimen to differing periods of observation, most of which ended with a recommended change in ART. Uncertainty over the time for resolution of gynecomastia remains and is influenced by etiology; idiopathic gynecomastia in children takes 0.8-2.6 years to resolve. 12 In adults, gynecomastia can be a transient phenomenon possibly reflecting a form of immune reconstitution 4 or resolve within a mean of approximately 5 months after withdrawal of EFV. 2 In a cohort of HIV-infected adult males receiving a variety of ART combinations (55% EFV), 20 of 21 of those followed for more than a year had spontaneous 14 Whilst rare it must be remembered that malignancy, especially lymphoma, can also present as breast enlargement.
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COMMENT
The overall prevalence of severe gynecomastia in children and young people living with HIV was 0.5%; most had been exposed to ART drugs known to be associated with the condition. Timely recognition of true drug-induced gynecomastia offers the possibility of noninvasive intervention as reversibility is more likely if gynecomastia has developed recently. The higher prevalence in males and a single severe case in a female may reflect the difficulty in diagnosing severe gynecomastia in peripubertal females. Considering the devastating potential impact of this condition on adherence in perinatally HIV-infected adolescents, prompt identification is important. Uncertainty remains about optimal management and it is critical to involve the patient in the decision making process. In our study, severe cases were more likely to have a low or normal BMI; in those with a higher BMI or just starting treatment, data from adults suggest a watch and wait approach for up to 9 months may be appropriate. However, where alternative treatments are available, an early switch to ART combinations with a more favorable metabolic profile is recommended.
